Fig. 1

Flowchart for inclusion and exclusion criteria. Final cohort consisted of 75 patients. Nine patients were excluded due to ‘other histology’, which in this case was primary cancer of the ovaries (n = 3), biliary tract (n = 2), papilla Vateri (n = 2), leiomyosarcoma (n = 1), and oesophagus (n = 1). Eight patients were excluded due to Gem/NabP not given as first line treatment; these had either received FOLFIRINOX (n = 4) or gembitabine (n = 1) first line, never started Gem/NabP (n = 2), or received Gem/NabP as third line treatment (n = 1)